Zoetis came into this Q3 2026 earnings release with the stock up over the past month, then the mood flipped. The share price dropped about 3% on the first full trading day after results, a sharp move for a mature animal health business that investors often treat as a steady franchise.
The headline story is pressure on profitability. Quarterly net income excluding extra items landed at US$591 million and basic EPS at US$1.44, both below Q2 levels, while adjusted guidance for full year earnings points to an expected decline versus last year. The market reacted fast. The financial hit will take longer to fully assess.
If you value the stability of Zoetis as a healthcare franchise but are concerned about recent earnings pressure and softer guidance, consider comparing it with a curated group of resilient businesses in our 32 resilient stocks with low risk scores
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025):US$2,391 million vs. US$2,422 million (down 1.3%)
-
Net Income excluding extra items (Q3 2026 vs. Q3 2025):US$591 million vs. US$721 million (down 18.0%)
-
Basic EPS (Q3 2026 vs. Q3 2025):US$1.44 vs. US$1.63 (down 11.8%)
-
Adjusted Gross Margin (Q3 2026):Approximately 71%, with management indicating an operational decline of about 0.6 percentage points year on year
Dermatology sales just fell 16% even as guidance improved. Ask Charlie what Zoetis is betting on after dermatology slumped .
Zoetis Bull Case Hangs On Offsets, Not Hype
The optimistic view assumes Zoetis can rely on new drugs and tighter execution to counter pricing and competition across core pet treatments.
"The main thing that has to go right is that Zoetis offsets competitive and pricing pressure in U.S. companion animal therapies by scaling new products, maintaining livestock and diagnostics momentum, and managing operating costs."
Q3 progress is mixed against that yardstick. Companion animal dermatology fell 16%, so competitive pressure is still a factor. At the same time, livestock climbed 7% and diagnostics rose 13%, which supports the idea of diversified revenue. Operating costs were flat on an adjusted basis, yet adjusted net income still declined 7% organically, so cost control alone is not fully bridging the gap today.
One Narrative has put a figure on that disagreement. → See the Narrative with its higher Fair Value, assumptions and all .
Zoetis Bear Case: Pressure Visible, Offsets Not Yet Proving Enough
The harsher view says Zoetis is leaning on a crowded pipeline while existing cash engines lose pricing power and share.
"The main thing that has to go right is that Zoetis converts its broad pipeline in areas like renal disease, oncology, cardiology, anxiety, obesity, osteoarthritis, and diagnostics into products that offset companion animal softness and heavier use of rebates and promotions."
Q3 does not disprove that concern. Companion animal revenue fell 5% and dermatology dropped 16%, while OA pain grew 2% and diagnostics 13%. Livestock rose 7%, yet adjusted net income declined 7% organically and gross margin compressed. The offsets are real, but not yet large enough to neutralize the pressures bearish analysts focus on.
Compare Zoetis Against Fresh Ideas
Zoetis shows that even established franchises can face earnings pressure and guidance reset risk. The real opportunity could be finding stocks that appear undervalued before consensus fully reflects their potential.
-
Company 1 - 15% below our estimate - targets power chips for AI servers, electric vehicles and industrial gear using silicon carbide and GaN platforms.
-
Company 2 - 23% below our estimate - builds a cardiometabolic and obesity drug portfolio supported by expanded manufacturing capacity and broader payer access.
-
Company 3 - 50% below our estimate - sells an AI driven revenue cycle platform that replaces fragmented billing tools as hospitals automate claims, denials and recoupments.
That is three of the list. See the full list of 41 companies trading below our fair value estimates →
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ZTS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
